{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:19:55Z","timestamp":1769109595465,"version":"3.49.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The outbreak of COVID-19 (caused by SARS-CoV-2) has posed a significant threat to global public health security because of its high pathogenicity and infectivity. To date, the pathogenic mechanism of this novel coronavirus (SARS-CoV-2) is still unclear, and there is no effective treatment. As one of the most effective strategies to prevent viral infection, vaccines have become a research hotspot. Based on the current understanding of SARS-CoV-2, the research and development of its vaccines cover almost all forms of current vaccine research, including inactivated vaccines, recombinant protein vaccines, viral vector vaccines, and nucleic acid vaccines. Moreover, with the spread of the new mutant virus, it is necessary to evaluate the protection rate of previous administered vaccines. This article reviews the candidate targets, vaccine types, research and development status, progress of SARS-CoV-2 vaccines, and the effectiveness of neutralizing antibodies against SARS-CoV-2 mutants (B.1.1.7, B.1.351, P.1, B.1.617.2, and B.1.1.529) induced by these vaccines, to provide a reference for follow-up research and prevention.<\/jats:p>","DOI":"10.3389\/fimmu.2022.804945","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T05:07:50Z","timestamp":1651122470000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants"],"prefix":"10.3389","volume":"13","author":[{"given":"Chaonan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yikai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongbiao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keda","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-020-00404-4","article-title":"SARS-CoV-2 and COVID-19: The Most Important Research Questions","volume":"10","author":"Yuen","year":"2020","journal-title":"Cell Biosci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and Its Immune Cross-Reactivity With SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B4","unstructured":"Genomic Epidemiology of Novel Coronavirus - Global Subsampling"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001316","article-title":"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine Phosphate has Shown Apparent Efficacy in Treatment of COVID-19 Associated Pneumonia in Clinical Studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-Ncov) In Vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/s20154289","article-title":"Point-Of-Care Diagnostics of COVID-19: From Current Work to Future Perspectives","volume":"20","author":"Hussein","year":"2020","journal-title":"Sensors (Basel)"},{"key":"B9","article-title":"SARS-CoV-2, SARS-CoV, and MERS-COV: A Comparative Overview","volume":"28","author":"Rabaan","year":"2020","journal-title":"Infez Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2021.05.021","article-title":"Rising to the Challenge of COVID-19: Working on SARS-CoV-2 During the Pandemic","volume":"81","author":"Stern-Ginossar","year":"2021","journal-title":"Mol Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-01696-3","article-title":"Delta Coronavirus Variant: Scientists Brace for Impact","volume":"595","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 Vaccines Against the B. 1.617. 2 (Delta) Variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/bs.aivir.2018.01.001","article-title":"Hosts and Sources of Endemic Human Coronaviruses","volume":"100","author":"Corman","year":"2018","journal-title":"Adv Virus Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00108-019-00671-5","article-title":"[Coronaviruses as the Cause of Respiratory Infections]","volume":"60","author":"Corman","year":"2019","journal-title":"Internist (Berl)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25709","article-title":"Overlapping and Discrete Aspects of the Pathology and Pathogenesis of the Emerging Human Pathogenic Coronaviruses SARS-CoV, MERS-CoV, and 2019-Ncov","volume":"92","author":"Liu","year":"2020","journal-title":"J Med Virol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, Function, and Evolution of Coronavirus Spike Proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu Rev Virol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: An Overview of Their Replication and Pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and Functional Properties of SARS-CoV-2 Spike Protein: Potential Antivirus Drug Development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacologica Sinica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nm1267","article-title":"A Crucial Role of Angiotensin Converting Enzyme 2 (ACE2) in SARS Coronavirus-Induced Lung Injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/v12030254","article-title":"Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies","volume":"12","author":"Ahmed","year":"2020","journal-title":"Viruses"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25736","article-title":"Development of Epitope-Based Peptide Vaccine Against Novel Coronavirus 2019 (SARS-COV-2): Immunoinformatics Approach","volume":"92","author":"Bhattacharya","year":"2020","journal-title":"J Med Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, With Potent Protection Against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.3390\/jcm10122629","article-title":"Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study Among Healthcare Workers in Turkey","volume":"10","author":"Riad","year":"2021","journal-title":"J Clin Med"},{"key":"B25","unstructured":"Indonesia Approves China's Sinovac Vaccine as Infections Surge"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological Considerations for COVID-19 Vaccine Strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.07.021","article-title":"SARS-CoV-2 Vaccine Development: Current Status","volume":"95","author":"Poland","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01258","article-title":"Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19","volume":"11","author":"Saha","year":"2020","journal-title":"Front Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050524","article-title":"Delivery Routes for COVID-19 Vaccines","volume":"9","author":"Park","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus Type-5 Vectored COVID-19 Vaccine: A Dose-Escalation, Open-Label, non-Randomised, First-in-Human Trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/ph14050406","article-title":"COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials","volume":"14","author":"Yan","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and Efficacy of the ChAdOx1 Ncov-19 Vaccine (AZD1222) Against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 Ncov-19 (AZD1222) Vaccine Against SARS-CoV-2 Variant of Concern 202012\/01 (B.1.1.7): An Exploratory Analysis of a Randomised Controlled Trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120686","article-title":"Nasal Vaccination Against SARS-CoV-2: Synergistic or Alternative to Intramuscular Vaccines","volume":"603","author":"Tiboni","year":"2021","journal-title":"Int J Pharm"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.098","article-title":"Immunogenic Potential of DNA Vaccine Candidate, ZyCoV-D Against SARS-CoV-2 in Animal Models","volume":"39","author":"Dey","year":"2021","journal-title":"Vaccine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.01.035","article-title":"Pharmacological Strategies to Prevent SARS-CoV-2 Infection and Treat the Early Phases of COVID-19","volume":"104","author":"Scarabel","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-02385-x","article-title":"India's DNA COVID Vaccine Is a World First - More are Coming","volume":"597","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101020","article-title":"Safety and Immunogenicity of a DNA SARS-CoV-2 Vaccine (ZyCoV-D): Results of an Open-Label, non-Randomized Phase I Part of Phase I\/II Clinical Study by Intradermal Route in Healthy Subjects in India","volume":"38","author":"Momin","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0247-3","article-title":"Delivery of mRNA Vaccines With Heterocyclic Lipids Increases Anti-Tumor Efficacy by STING-Mediated Immune Cell Activation","volume":"37","author":"Miao","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, Safety, and Immunogenicity of an Enterovirus 71 Vaccine in China","volume":"370","author":"Zhu","year":"2014","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.09.061","article-title":"Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated With Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement","volume":"38","author":"Chen","year":"2020","journal-title":"Vaccine"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A Universal Design of Betacoronavirus Vaccines Against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and Immunogenicity of a Recombinant Tandem-Repeat Dimeric RBD-Based Protein Subunit Vaccine (ZF2001) Against COVID-19 in Adults: Two Randomised, Double-Blind, Placebo-Controlled, Phase 1 and 2 Trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.01.429069","article-title":"Neutralization of SARS-CoV-2 VOC 501y. V2 by Human Antisera Elicited by Both Inactivated BBIBP-CorV and Recombinant Dimeric RBD ZF2001 Vaccines","author":"Huang","year":"2021"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1101\/2020.12.20.20248602","article-title":"Safety and Immunogenicity of a Recombinant Tandem-Repeat Dimeric RBD Protein Vaccine Against COVID-19 in Adults: Pooled Analysis of Two Randomized, Double-Blind, Placebo-Controlled, Phase 1 and 2 Trials","volume":"21","author":"Yang","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.20.161323","article-title":"The D614G Mutation of SARS-CoV-2 Spike Protein Enhances Viral Infectivity","author":"Hu","year":"2020"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060588","article-title":"Comparison and Analysis of Neutralizing Antibody Levels in Serum After Inoculating With SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans","volume":"9","author":"Yu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03681-2","article-title":"Immunogenicity of Ad26.COV2.S Vaccine Against SARS-CoV-2 Variants in Humans","volume":"596","author":"Alter","year":"2021","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n296","article-title":"Covid-19: Novavax Vaccine Efficacy is 86% Against UK Variant and 60% Against South African Variant","volume":"372","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"B51","unstructured":"Sinopharm COVID-19 Vaccine (BBIBP-CorV)"},{"key":"B52","unstructured":"Third Time\u2019s the Charm? Brazil Scales Back Efficacy Claims for COVID-19 Vaccine From China"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2277","article-title":"Potency of BNT162b2 and mRNA-1273 Vaccine-Induced Neutralizing Antibodies Against Severe Acute Respiratory Syndrome-CoV-2 Variants of Concern: A Systematic Review of In Vitro Studies","author":"Noori","year":"2021","journal-title":"Rev Med Virol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2106083","article-title":"BNT162b2-Elicited Neutralization Against New SARS-CoV-2 Spike Variants","volume":"385","author":"Liu","year":"2021","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 Vaccines Against the B.1.617.2 (Delta) Variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.15.452504","article-title":"Neutralization of Recombinant RBD-Subunit Vaccine ZF2001-Elicited Antisera to SARS-CoV-2 Variants Including Delta","author":"Zhao","year":"2021"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2103022","article-title":"Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization","volume":"384","author":"Wang","year":"2021","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 Ncov-19 Covid-19 Vaccine Against the B.1.351 Variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01313-21","article-title":"Serum Neutralizing Activity of mRNA-1273 Against SARS-CoV-2 Variants","volume":"95","author":"Choi","year":"2021","journal-title":"J Virol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abj1750","article-title":"SARS-CoV-2 Variants of Concern Partially Escape Humoral But Not T-Cell Responses in COVID-19 Convalescent Donors and Vaccinees","volume":"6","author":"Geers","year":"2021","journal-title":"Sci Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119426","article-title":"Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant","volume":"386","author":"Zhao","year":"2022","journal-title":"New Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2102017","article-title":"Neutralizing Activity of BNT162b2-Elicited Serum","volume":"384","author":"Liu","year":"2021","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.Cov2.S Vaccine Against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01386-21","article-title":"B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies","volume":"12","author":"Zhou","year":"2021","journal-title":"mBio"},{"key":"B66","first-page":"1\u201312","article-title":"Vaccine Efficacy in Mutant SARS-CoV-2 Variants","volume":"4","author":"Kandikattu","year":"2021","journal-title":"Int J Cell Biol Physiol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2103740","article-title":"Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351","volume":"384","author":"Shen","year":"2021","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1041","article-title":"Neutralization of SARS-CoV-2 Omicron Variant by Sera From BNT162b2 or Coronavac Vaccine Recipients","author":"Lu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.01.433466","article-title":"Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization","volume":"29","author":"Wang","year":"2021","journal-title":"bioRxiv"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3822780","article-title":"Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study","author":"Palacios","year":"2021"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taac036","article-title":"Similar Effectiveness of the Inactivated Vaccine BBIBP-CorV (Sinopharm) and the mRNA Vaccine BNT162b2 (Pfizer-BioNTech) Against COVID-19 Related Hospitalizations During the Delta Outbreak in the United Arab Emirates","author":"Mousa","year":"2022","journal-title":"J Travel Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41579-019-0213-6","article-title":"Microbial Genes and Pathways in Inflammatory Bowel Disease","volume":"17","author":"Schirmer","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron Extensively But Incompletely Escapes Pfizer BNT162b2 Neutralization","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.12.472269","article-title":"Broadly Neutralizing Antibodies Overcome SARS-CoV-2 Omicron Antigenic Shift. Biorxiv","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.14.21267755","article-title":"mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-CoV-2 Omicron Variant","volume":"185","author":"Garcia-Beltran","year":"2021"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.12.014","article-title":"COVID-19 mRNA Booster Vaccines Elicit Strong Protection Against SARS-CoV-2 Omicron Variant in Patients With Cancer","author":"Zeng","year":"2021","journal-title":"Cancer Cell"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.03.471045","article-title":"Omicron-B.1.1.529 Leads to Widespread Escape From Neutralizing Antibody Responses","author":"Dejnirattisai","year":"2021","journal-title":"bioRxiv"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04399-5","article-title":"Activity of Convalescent and Vaccine Serum Against SARS-CoV-2 Omicron","author":"Carre\u00f1o","year":"2021","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.12.472286","article-title":"The Omicron Variant is Highly Resistant Against Antibody-Mediated Neutralization\u2013Implications for Control of the COVID-19 Pandemic","author":"Hoffmann","year":"2021"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-0758-8_27","article-title":"Microneutralization Assay for Swine Influenza Virus in Swine Serum","volume":"1161","author":"Kitikoon","year":"2014","journal-title":"Methods Mol Biol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.16.2000421","article-title":"Serological Assays for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), March 2020","volume":"25","author":"Perera","year":"2020","journal-title":"Euro Surveill"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-00720-9","article-title":"COVID-19 Vaccines: Where We Stand and Challenges Ahead","volume":"28","author":"Forni","year":"2021","journal-title":"Cell Death Differ"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 Vaccine Against the B.1.1.7 and B.1.351 Variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.25.427948","article-title":"mRNA-1273 Vaccine Induces Neutralizing Antibodies Against Spike Mutants From Global SARS-CoV-2 Variants","author":"Wu","year":"2021"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.23.441101","article-title":"Neutralization of Variant Under Investigation B. 1.617 With Sera of BBV152 Vaccinees","author":"Yadav","year":"2021"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taab119","article-title":"Neutralization of Delta Variant With Sera of Covishield\u2122 Vaccinees and COVID-19-Recovered Vaccinated Individuals","volume":"28","author":"Sapkal","year":"2021","journal-title":"J Travel Med"},{"key":"B88","volume-title":"Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern","year":"2021"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 Variant: A New Chapter in the COVID-19 Pandemic","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"B90","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41392-021-00852-5","article-title":"SARS-CoV-2 Omicron Strain Exhibits Potent Capabilities for Immune Evasion and Viral Entrance","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.14.472630","article-title":"Considerable Escape of SARS-CoV-2 Variant Omicron to Antibody Neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00648-4","article-title":"Community Transmission and Viral Load Kinetics of the SARS-CoV-2 Delta (B.1.617.2) Variant in Vaccinated and Unvaccinated Individuals in the UK: A Prospective, Longitudinal, Cohort Study","volume":"22","author":"Singanayagam","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02046-8","article-title":"Considerations in Boosting COVID-19 Vaccine Immune Responses","volume":"398","author":"Krause","year":"2021","journal-title":"Lancet"},{"key":"B94","unstructured":"Novavax may Combine the Flu and COVID-19 Vaccines Together"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00226","article-title":"Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses","volume":"7","author":"Vangelista","year":"2020","journal-title":"Front Mol Biosci"},{"key":"B96","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12967-020-02363-3","article-title":"Allo-Priming as a Universal Anti-Viral Vaccine: Protecting Elderly From Current COVID-19 and Any Future Unknown Viral Outbreak","volume":"18","author":"Har-Noy","year":"2020","journal-title":"J Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.804945\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T05:08:00Z","timestamp":1651122480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.804945\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":96,"alternative-id":["10.3389\/fimmu.2022.804945"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.804945","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"article-number":"804945"}}